IWC
AMLX icon

Integrated Wealth Concepts’s Amylyx Pharmaceuticals AMLX Stock Holding History

Integrated Wealth Concepts’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,641
Closed -$157K – 1645
2023
Q4 		$157K Buy
10,641
+285
+3% +$4.37K ﹤0.01% 1498
2023
Q3 		$190K Hold
10,356
– – ﹤0.01% 1424
2023
Q2 		$223K Sell
10,356
-12
-0.1% -$324 ﹤0.01% 1372
2023
Q1 		$304K Sell
10,368
-2,000
-16% -$69.5K 0.01% 1051
2022
Q4 		$457K Buy
+12,368
New +$439K 0.01% 678

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Integrated Wealth Concepts's AMLX Position: Q1 2024 in Review

Integrated Wealth Concepts sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2024, closing a stake of 10,641 shares — an estimated $157K sold.

Integrated Wealth Concepts first reported a position in AMLX in Q4 2022 and held it in 5 quarters. The position peaked at $457K in Q4 2022. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

  • Integrated Wealth Concepts reported no remaining Amylyx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Integrated Wealth Concepts sold 10,641 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $157K.
  • Integrated Wealth Concepts first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Integrated Wealth Concepts's Amylyx Pharmaceuticals position peaked at $457K in Q4 2022.
  • 143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on Integrated Wealth Concepts's 13F filing for Q1 2024, filed 15 May 2024.